TataMD has announced the launch of CHECK
Tata Medical and Diagnostics Ltd (TataMD), the healthcare venture from Tata Group, has announced the commercial launch of TataMD CHECK, novel diagnostic testing for COVID-19. TataMD CHECK is powered by FELUDA, a CRISPR Cas-9 technology that was developed in India by CSIR- IGIB for COVID testing. It is the world’s first CRISPR Cas-9 based diagnostic tool to be launched globally.
Commenting on the launch, Girish Krishnamurthy, CEO, Tata Medical and Diagnostics said, “With TataMD CHECK, we are committed to significantly enhance the testing experience of the consumers as well as work with laboratories and hospitals to ensure wider availability and easier access to testing.” The test kits will be manufactured at a Chennai production facility, which presently has a capacity of producing one million kits in a month.
Outlining the advantages of TataMD Check testing, the company said that it was a paper strip-based test with an image-based visual result read out. It requires standard laboratory equipment and small batches of tests can be conducted, which simplifies the diagnostics process.
The test reaction time in a laboratory is 45-50 minutes and the total testing time from RNA-extracted sample in the lab to result is 75 minutes only. Additionally, it can provide high quality, quick results using standard equipment and minimally trained staff. This allows for rapid adoption and scale with potential to reach remote locations of the country.
TataMD does continuous quality control using sensors and AI-based result reporting tool. This helps patients and authorities with the traceability of the sample and to access the results anywhere, since the findings are stored on cloud storage.
source:https://www.healthcareradius.in/clinical/27030-tatamd-launches-check-a-diagnostic-testing-technology-for-covid-19